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Summary
Disease characteristics. Episodic ataxia type 1 (EA1) is a potassium channelopathy characterized by constant myokymia and
dramatic episodes of spastic contractions of the skeletal muscles of the head, arms, and legs with loss of both motor
coordination and balance. During attacks some individuals may experience vertigo, blurred vision, diplopia, nausea, headache,
diaphoresis, clumsiness, stiffening of the body, dysarthric speech, and difficulty in breathing. EA1 is associated with an increased
incidence of epilepsy. Other findings can include delayed motor development, cognitive disability, choreoathetosis, and carpal
spasm. Onset is in childhood or early adolescence.
Diagnosis/testing. Diagnosis is based on clinical findings and molecular genetic testing of KCNA1, the only gene in which
mutations are known to cause EA1.
Management. Treatment of manifestations: Acetazolamide (ACTZ), a carbonic-anhydrase (CA) inhibitor, may reduce the
frequency and severity of the attacks in some but not all affected individuals. Antiepileptic drugs (AEDs) may significantly
reduce the frequency of the attacks in some individuals.
Prevention of primary manifestations: In addition to pharmacologic treatments, behavioral measures including avoidance of
stress, abrupt movements, loud noises, and caffeine intake may be used to reduce disease manifestations both in a symptomatic
or an asymptomatic person.
Prevention of secondary complications: Joint contractures can be prevented by appropriate physiotherapy.
Surveillance: Annual neurologic examination.
Agents/circumstances to avoid: General anesthetics have occasionally been reported to precipitate or aggravate neuromyotonia
Genetic counseling. EA1 is inherited in an autosomal dominant manner. Most individuals diagnosed with EA1 have an
affected parent; to date, only one de novo mutation has been reported. Each child of an individual with EA1 has a 50% chance of
inheriting the mutation. Prenatal diagnosis for pregnancies at increased risk is possible if the disease-causing mutation has been
identified in an affected family member.
Diagnosis
Clinical Diagnosis
Episodic ataxia type 1 (EA1), a neurologic disease resulting from alterations in the voltage-gated potassium channel (Kv1.1), is
suspected in individuals with the following clinical findings:
Attacks of: generalized ataxia with jerking movements of head, arms, and legs; stiffening of the body; loss of balance;
dizziness; blurred vision; dysarthria; and diplopia. These episodes may occur several times a month, may last seconds to
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minutes, and can be precipitated by anxiety, emotional stress, fatigue, startle response, and sudden postural changes
(kinesigenic stimulation). Mild exercise, kinesigenic stimulation, and vestibular caloric stimulation may be used to induc
attacks.
Neuromyotonia (muscle cramps and stiffness) and myokymia (muscle twitching with a rippling appearance) may
occur in the limbs or especially in the muscles of the face or the hands. Evidence of myokymia, detected by
electromyography (EMG), is found in nearly all individuals with EA1 regardless of clinical findings. The EMG displays a
pattern of either rhythmically or arrhythmically occurring singlets, duplets, or multiplets. Note: In some individuals
myokymic activity on the EMG becomes apparent after the application of regional ischemia.
Childhood or early-adolescent disease onset
Family history consistent with autosomal dominant inheritance
Testing
Axonal superexcitability and threshold electrotonus may be investigated by means of a simple and rapid electrophysiologic test
that can differentiate individuals with EA1 from normal controls with high sensitivity and specificity [Tomlinson et al 2010].
Brain MRI and routine laboratory blood tests, including serum concentration of creatine kinase and electrolytes, are generally
normal.
Muscle biopsy is usually not helpful in establishing the diagnosis, although bilateral calf hypertrophy, enlargement of type 1 and
type 2 gastrocnemius muscle fibers, and variable glycogen depletion have been reported [Van Dyke et al 1975, Kinali et al 2004,
Demos et al 2009]. Nevertheless, these changes have not been consistently reported among individuals with EA1.
Molecular Genetic Testing
Gene. KCNA1 is the only gene in which mutations are known to cause episodic ataxia type 1.
Clinical testing
Table 1. Summary of Molecular Genetic Testing Used in Episodic Ataxia Type 1
Gene
Symbol Test Method Mutations Detected
Mutation Detection Frequency by Test
Method 
Test
Availability
KCNA1
Sequence analysis Sequence variants >90% 
Clinical
Deletion / duplication
analysis
Deletions /
duplications Unknown; none reported 
Test Availability refers to availability in the GeneTests™ Laboratory Directory. GeneReviews designates a molecular genetic test as clinically available
only if the test is listed in the GeneTests™ Laboratory Directory by either a US CLIA-licensed laboratory or a non-US clinical laboratory. GeneTests does
not verify laboratory-submitted information or warrant any aspect of a laboratory's licensure or performance. Clinicians must communicate directly
with the laboratories to verify information.
1. The ability of the test method used to detect a mutation that is present in the indicated gene
2. Examples of mutations detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site
mutations; typically, exonic or whole gene deletions/duplications are not detected.
3. All affected individuals described thus far are heterozygous for KCNA1 mutations at amino acid residues highly conserved among the voltage-
dependent K  channel superfamily.
4. Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA
included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA),
and chromosomal microarray (CMA) that includes this gene/chromosome segment. See CMA.
5. No deletions or duplications involving KCNA1 have been reported to cause episodic ataxia type 1.
Interpretation of test results
For issues to consider in interpretation of sequence analysis results, click here.
For KCNA1 sequence variants, publications on in vitro assessment of channel function may be useful [Imbrici et al 2008]
Channel function assays are not offered on a clinical testing basis.
Information on specific allelic variants may be available in Molecular Genetics (see Table A. Genes and Databases and/or
Pathologic allelic variants).
Testing Strategy
To confirm/establish the diagnosis in a proband
To induce attacks:
Mild exercise (knee bends; running up a staircase quickly; arising from a chair quickly)
1
2 3
4
5
+
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Vestibular stimulation (head turning from side to side while standing still; sitting still on a rotating chair;
instillation of cold water (i.e., ≤30° C) into either external auditory canal)
Sudden and unexpected tactile or acoustic stimuli causing a startle response (rising quickly after a loud handclap)
To evaluate for interictal motor activity (neuromyotonia/myokymia) in individuals who report characteristic episodes:
surface or needle EMG recordings are performed before, during, and after the application of regional ischemia (e.g., using
an inflated sphygmomanometer cuff applied around the upper or lower arm for up to 15 minutes).
Usually, sequence analysis of KCNA1 is recommended as a confirmatory diagnostic test.
Although no deletions of KCNA1 have been reported to cause EA1, it is theoretically possible that such mutations exist.
Therefore, deletion/duplication analysis may be useful in individuals displaying EA1 symptoms if sequence analysis does
not identify a disease-causing KCNA1 mutation.
Prenatal diagnosis and preimplantation genetic diagnosis (PGD) for at-risk pregnancies require prior identification of
the disease-causing mutation in the family.
Note: It is the policy of GeneReviews to include in GeneReviews™ chapters any clinical uses of testing available from
laboratories listed in the GeneTests™ Laboratory Directory; inclusion does not necessarily reflect the endorsement of such uses
by the author(s), editor(s), or reviewer(s).
Genetically Related (Allelic) Disorders
Eunson et al [2000] reported a unique phenotype characterized by isolated neuromyotonia without episodes of ataxia in
association with a mutation in KCNA1. It is unclear whether this truly represents a unique phenotype or falls within the
phenotypic spectrum of episodic ataxia type 1.
Hypomagnesemia with accompanying recurrent muscle cramps, tetanic episodes, tremor, and limb muscle weakness has been
described in a large Brazilian family harboring a KCNA1 mutation [Glaudemans et al 2009].
Clinical Description
Natural History
Episodic ataxia type 1 (EA1), first described in 1975 by Van Dyke et al, is a potassium channelopathy characterized by constant
myokymia and dramatic episodes of spastic contractions of the skeletal muscles of the head, arms, and legs with loss of both
motor coordination and balance. During attacks some individuals may experience vertigo, blurred vision, diplopia, nausea,
headache, diaphoresis, clumsiness, stiffening of the body, dysarthric speech, and difficulty in breathing [Van Dyke et al1975].
The duration of the attacks is brief, lasting seconds to minutes, although prolonged attacks of five to 12 hours have been
described [Lee et al 2004a]. Some individuals experience severe ataxia more than 15 times per day, whereas others experience
attacks less often than once a month [Van Dyke et al 1975].
The first symptoms typically manifest during childhood (1st or 2nd decade of life). A specific traumatic physical or emotional
event may determine the onset and worsening of the disease [Imbrici et al 2008]. Attacks may be brought on by stimuli
including fever, startle response, abrupt movements, emotional stress, anxiety, repeat knee bends, exercise, ingestion of caffeine
and riding a merry-go-round. Attacks may occur, for example, when the individual has had to suddenly alter course to avoid
falling or potential collision. High temperatures that occur after a hot bath or during use of a hairdryer may also precipitate
attacks [Eunson et al 2000]. Whether interictal ataxia develops in individuals with EA1 has not been clearly reported to date.
Myokymia manifests clinically during and between attacks as fine twitching of groups of muscles and intermittent cramps and
stiffness. Usually, it is evident as a fine rippling in perioral or periorbital muscles and by lateral finger movements when the
hands are held in a relaxed, prone position.
Rarely, episodes of intense myokymic activity during attacks without either ataxia or other neurologic deficits are observed.
Myokymic activity is continuous.
The exposure of the forearm to warm or cold temperatures may increase or decrease, respectively, the spontaneous activity
recorded from a hand muscle.
The severity of some symptoms may either improve or worsen with age [Imbrici et al 2008].
Since the first description of EA1 by Van Dyke et al [1975] and the identification and characterization of mutations in KCNA1, th
phenotypic spectrum of EA1 has widened considerably, indicating that it is not a purely cerebellar syndrome. Affected
individuals may display delayed motor development, choreoathetosis, carpal spasm, clenching of the fists, and isolated
neuromyotonia.
Cognitive dysfunction described in EA1 includes severe receptive and expressive language delay; inability to learn to ride a
bicycle; and the need for life-skill programs or schools for children with mild to moderate learning difficulties [Zuberi et al 1999
Demos et al 2009].
Moderate muscle hypertrophy with generalized increase in muscle tone and bilateral calf hypertrophy are observed.
Neuromuscular findings secondary to the increased tone include unusual hypercontracted posture; abdominal wall muscle
contraction; elbow, hip, and knee contractures; and shortened Achilles tendons that may result in tiptoe walking.
Some individuals display attacks of difficulty in breathing, which can occur during ataxic episodes or as isolated episodes of an
inability to inhale without wheezing [Shook et al 2008].
Skeletal deformities including scoliosis, kyphoscoliosis, high-arched palate, and minor craniofacial dysmorphism have been
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described [Kinali et al 2004, Klein et al 2004]. It is now apparent that phenotypic differences exist not only between families,
but also between individuals of the same family.
Tonic-clonic and partial seizures, an isolated episode consisting of photo-sensitive epilepsy [Imbrici et al 2008], as well as
head-turning and eyes deviating to the same side, flickering eyelids, lip-smacking, apnea, and cyanosis have been reported
[Zuberi et al 1999].
Abnormal electroencephalograms (EEG) have been observed in persons with EA1 [Van Dyke et al 1975, Zuberi et al 1999, Lee et
al 2004a]. EEG may be characterized by intermittent and generalized slow activity, frequently intermingled with spikes. Zuberi
et al [1999] described a three-year-old boy who presented with an ictal EEG with rhythmic slow-wave activity over the right
hemisphere, becoming spike-and-wave complexes that subsequently spread to the left hemisphere.
Neuromimaging with MRI is usually normal; however, Demos et al [2009] reported a family with cerebellar atrophy.
Genotype-Phenotype Correlations
Due to significant interfamilial and intrafamilial phenotypic variability, reliable genotype-phenotype correlations have been
extremely difficult to establish. Indeed, differences in severity and frequency of EA1 attacks have been reported even in
monozygotic twins [Graves et al 2010].
Penetrance
Most individuals harboring a KCNA1 mutation exhibit features of EA1; however, penetrance is incomplete.
Nomenclature
EA1 has also been known as:
Familial paroxysmal kinesigenic ataxia and continuous myokymia
Acetazolamide-responsive periodic ataxia
Continuous muscle fiber activity
Isaacs-Mertens syndrome
Prevalence
EA1 is a rare disease and the prevalence can be estimated only roughly. At present, several families from the United States,
Brazil, United Kingdom, The Netherlands, Australia, Italy, Spain, and Russia have been described. Based on limited data, a
disease prevalence of 1:500,000 has been proposed. Actual prevalence may well be considerably higher, as the disorder may
remain either unrecognized in many families or be incorrectly diagnosed.
The populations that are more or less at risk are also unknown.
Differential Diagnosis
For current information on availability of genetic testing for disorders included in this section, see GeneTests Laboratory
Directory. —ED.
Table 2. Episodic Ataxia: OMIM Phenotypic Series
Phenotype Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
Episodic ataxia/myokymia syndrome 160120 KCNA1, AEMK, EA1 176260
Episodic ataxia, type 2 108500 CACNA1A, CACNL1A4, SCA6 601011
Episodic ataxia, type 3 606554 EA3 606554
Episodic ataxia, type 4 606552 EA4, PATX 606552
Episodic ataxia, type 5 613855 CACNB4, EJM6, EA5, EIG9 601949
Episodic ataxia, type 6 612656 SLC1A3, EAAT1, EA6 600111
Episodic ataxia, type 7 611907 EA7 611907
Data from Online Mendelian Inheritance in Man
Episodic ataxia can occur sporadically or in a number of hereditary disorders:
Episodic ataxia type 2 (EA2) is characterized by paroxysmal attacks of ataxia, vertigo, and nausea typically lasting
minutes to days in duration. Stress, exertion, caffeine, and alcohol may trigger attacks that can be associated with
dysarthria, diplopia, tinnitus, dystonia, hemiplegia, and headache. Approximately 50% of individuals with EA2 have
migraine headaches. Onset is typically in childhood or early adolescence. MRI can demonstrate atrophy of the cerebellar
vermis. EA2 is inherited in an autosomal dominant manner. Mutations in CACNA1A, which encodes for a voltage-
dependent Ca  channel alpha subunit, can cause this disease.2+
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Episodic ataxia type 3 (EA3) [OMIM 606554] has been described in two families of northern European origin from
rural North Carolina by Farmer & Mustian [1963] and Vance et al [1984]. A relationship between the two kindreds is
suspected but has not been established. EA3 is characterized by attacks of vertigo, diplopia, and ataxia beginning in early
adulthood. In some individuals, slowly progressive cerebellar ataxia occurs. This condition does not link to loci identified
with EA1, EA2, or spinocerebellar ataxia types 1, 2, 3, 4, and 5 [Damji et al 1996]. A candidate region on chromosome 1q42
has been identified [Cader et al 2005].
Episodic ataxia type 4 (EA4) [OMIM 606552] has been described in a large Canadian Mennonite family [Steckley et a
2001]. EA4 is also known as familial periodic vestibulocerebellar ataxia and is characterized by brief acetazolamide-
responsive attacks of vestibular ataxia, vertigo, tinnitus, and interictal myokymia. Interictal nystagmus and ataxia were
not identified. The age of onset is variable. The gene defect that underlies EA4 is not known; EA4 does not link to the loci
for EA1 or EA2.
Episodic ataxia type 5 (EA5) [OMIM 601949] can result from a mutation in CACNB4, encoding the beta-4 isoform of
the regulatory beta subunit of voltage-activated Ca(2+) channels. A c.311G>T (p.Cys104Phe; reference sequences
NM_000726.3; NP_000717.2) mutation has been described in a French-Canadian family [Escayg et al 2000]. The
phenotype was characterized by recurrent episodes of vertigo and ataxia that lasted for several hours. Interictal
examination showed spontaneous downbeat and gaze-evoked nystagmus and mild dysarthria and truncal ataxia.
Acetazolamide prevented the attacks. EA5 is allelic with juvenile myoclonic epilepsy (JME); the semiology of seizures in
EA5 is similar to JME.
Episodic ataxia type 6 (EA6) [OMIM 612656] is characterized by attacks of ataxia precipitated by fever, subclinical
seizures, slurred speech followed by headache, and bouts of arm jerking with concomitant confusion and alternating
hemiplegia. EA6 can result from mutations in SLC1A3, which encodes the excitatory amino acid transporter 1 (EAAT1). In
cells expressing mutated proteins, glutamate uptake is reduced, suggesting that glutamate transporter dysfunction
underlies the disease [Jen et al 2005, de Vries et al 2009].
Episodic ataxia type 7 (EA7) [OMIM 611907] has been described in a four-generation family whose affected
individuals showed episodic ataxia before age 20 years [Kerber et al 2007]. The disease is characterized by attacks
associated with weakness, vertigo, and dysarthria lasting hours to days. Attacks may be brought about by exercise and
excitement. A candidate region on chromosome 19q13, termed the EA7 locus, has been identified [Kerber et al 2007].
Autosomal dominant spastic ataxia (ADSA) [OMIM 108600]. Affected individuals initially show progressive leg
spasticity of variable degree followed by ataxia in the form of involuntary head jerk, dysarthria, dysphagia, and ocular
movement abnormalities. The age at onset is from early childhood to early twenties. Linkage studies identified a locus on
12p13, termed SAX1 [Meijer et al 2002].
Familial paroxysmal kinesigenic dyskinesia (PKD) is characterized by attacks of dystonia, choreoathetosis, and
ballism that last seconds to hours and are sometimes preceded by an aura and precipitated by sudden movements, cold,
hyperventilation, and mental tension. Attacks can be as frequent as 100 per day to as few as one per month. Age of onset
is typically in childhood [Bruno et al 2004]. Familial PKD is inherited in an autosomal dominant manner; the gene(s)
associated with PKD have not been identified. Linkage of familial PKD to 16q11.2-q22.1 has been established in several
families with PKD [Tomita et al 1999, Bennett et al 2000, Valente et al 2000].
Familial paroxysmal nonkinesigenic dyskinesia (PNKD) is characterized by attacks of dystonia, chorea, ballismus
or athetosis provoked by alcohol, caffeine, excitement, stress, or fatigue. Attacks are not typically triggered by movement,
may be accompanied by a preceding aura, last minutes to hours, and rarely occur more than once per day. Age of onset is
typically in childhood or early teens. Familial PNKD is inherited in an autosomal dominant manner; PNKD, encoding
myofibrillogenesis regulator 1, is the only gene known to be associated with this disease [Lee et al 2004b, Rainier et al
2004, Chen et al 2005a]. A second locus for familial PNKD has been identified on chromosome 2q31 in a Canadian family
of European descent [Spacey et al 2006].
Isaacs syndrome (acquired neuromyotonia, NMT) is a rare neuromuscular disorder characterized by hyperexcitability
of the motor nerve that results in continuously contracting or twitching muscles (myokymia) and muscle hypertrophy.
Individuals also experience cramping, increased sweating, and delayed muscle relaxation. Stiffness is most prominent in
limb and trunk muscles. Symptoms are not usually triggered by exercise and occur even during sleep or when individuals
are under general anesthesia. A few affected individuals report sleep disorders, anxiety, and memory loss (Morvan
syndrome). Onset is between ages 15 and 60 years. The acquired form occasionally develops in association with periphera
neuropathies or after radiation treatment. Twenty percent of affected individuals have an associated thymoma. Antibodie
to voltage-gated potassium channels are detected in approximately 40% of affected individuals [Hart et al 2002]. It has
been shown that antibodies bind variably to the Kv1.1- and 1.2-containing juxtaparanodes of peripheral and central
myelinated axons [Kleopa et al 2006].
Note to clinicians: For a patient-specific ‘simultaneous consult’ related to this disorder, go to , an
interactive diagnostic decision support software tool that provides differential diagnoses based on patient findings (registration
or institutional access required).
Management
Evaluations Following Initial Diagnosis
To establish the extent of disease in an individual diagnosed with episodic ataxia type 1, the following evaluations are
recommended:
Detailed medical history of the individual
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Neurologic examination
Initiation (and observation) of attacks of ataxia by either mild exercise or vestibular stimuli
EMG to confirm the presence of myokymia, particularly if it is not visible on examination
EEG to look for epilepsy [Zuberi et al 1999, Eunson et al 2000, Chen et al 2007]
Medical genetics consultation
Treatment of Manifestations
Acetazolamide (ACTZ), a carbonic-anhydrase (CA) inhibitor, may reduce the frequency and severity of the attacks in some
but not all affected individuals. The mechanism by which ACTZ reduces the frequency and severity of the attacks is unclear. The
recommended starting dosage is 125 mg once a day, given orally. However, individuals with good renal function may require
higher daily doses, ranging from 8 to 30 mg/kg/day in one to four divided doses (not to exceed 1 g/day). ACTZ should not be
prescribed to individuals with liver, renal, or adrenal insufficiency.
Chronic treatment with ACTZ may result in side effects including paresthesias, rash, and formation of renal calculi.
Antiepileptic drugs (AEDs) may significantly reduce the frequency of the attacks in responsive individuals; however, the
response is heterogeneous as some individuals are particularly resistant to drugs [Eunson et al 2000].
Diphenylhydantoin treatment at a dose of 150-300 mg daily resulted in reasonable control of seizures in some
individuals [Van Dyke et al 1975]. In particular, phenytoin treatment at a dose of 3.7 mg/kg/day may improve muscle
stiffness and motor performance [Kinali et al 2004]. Nevertheless, phenytoin should be used with caution in young
individuals, as it may cause permanent cerebellar dysfunction and atrophy [De Marco et al 2003].
Sulthiame 50-200 mg daily may reduce the attack rate. During this treatment abortive attacks were still noticed lasting 
few seconds and troublesome side effects were paresthesias and intermittent carpal spasm.
Carbamazepine up to 1600 mg daily [Eunson et al 2000]. However, the dose needs to be adjusted according to differen
factors including, age, weight, the particular carbamazepine product being used, responsiveness of the individual, and
other medications being taken.
Prevention of Primary Manifestations
In addition to the pharmacologic treatments mentioned above behavioral measures, such as avoidance of stress, abrupt
movements, loud noises or caffeine intake may be used to reduce disease manifestations in either a symptomatic or an
asymptomatic person.
Prevention of Secondary Complications
Contractures occur in a small proportion of individuals and can be prevented by appropriate physiotherapy.
Surveillance
Surveillance should include annual neurologic examination.
Agents/Circumstances to Avoid
General anesthetics have occasionally been reported to precipitate or aggravate neuromyotonia [Eunson et al 2000].
Evaluation of Relatives at Risk
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
Pregnancy Management
No published literature addresses management of the pregnancy of an affected mother or the effect of maternal EA1 on a fetus.
However, the mother should be made aware that during attacks, loss of balance and falls could endanger the fetus’s life. Several
stressors trigger attacks that may cause breathing difficulties, thus, delivery by C-section should be considered.
Therapies Under Investigation
Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions. Note: There
may not be clinical trials for this disorder.
Other
Morphologic studies on lateral gastrocnemius (LG) muscles derived from a mouse model of EA1 did not reveal changes in
muscle mass, fiber type composition, or vascularization [Brunetti et al 2012].
Homozygous V408A/V408A mutations are embryonically lethal in an animal model of EA1 [Herson et al 2003], although this
has not been reported in humans.
Genetics clinics, staffed by genetics professionals, provide information for individuals and families regarding the natural
history, treatment, mode of inheritance, and genetic risks to other family members as well as information about available
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consumer-oriented resources. See the GeneTests Clinic Directory.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and
implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with
genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This
section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for
consultation with a genetics professional. To find a genetics or prenatal diagnosis clinic, see the GeneTests Clinic Directory.
Mode of Inheritance
Episodic ataxia type 1 is inherited in an autosomal dominant manner.
Risk to Family Members
Parents of a proband
Most individuals diagnosed with episodic ataxia type 1 have an affected parent.
A proband with episodic ataxia type 1 may have the disorder as the result of a new gene mutation. To date, only one de
novo mutation has been identified [Demos et al 2009].
If the disease-causing mutation found in the proband cannot be detected in the DNA of either parent, two possible
explanations are germline mosaicism in a parent or a de novo mutation in the proband. Although no instances of
germline mosaicism have been reported, it remains a possibility.
Recommendations for the evaluation of parents of a proband with an apparent de novo mutation include accurate
neurologic evaluation and sequence analysis of KCNA1. Evaluation of parents may determine that one is affected but has
escaped previous diagnosis because of a milder phenotypic presentation. Therefore, an apparently negative family history
cannot be confirmed until appropriate evaluations have been performed.
Note: (1) Although most individuals diagnosed with episodic ataxia type 1 have an affected parent, the family history may appear
to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of
symptoms, or late onset of the disease in the affected parent. (2) If the parent is the individual in whom the mutation first
occurred s/he may have somatic mosaicism for the mutation and may be mildly/minimally affected.
Sibs of a proband
The risk to the sibs of the proband depends on the genetic status of the proband’s parents.
If a parent of the proband is affected, the risk to the sibs is 50%.
When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.
The sibs of a proband with clinically unaffected parents are still at increased risk for the disorder because of the
possibility of reduced penetrance in a parent.
If the disease-causing mutation found in the proband cannot be detected in the DNA of either parent, the risk to sibs is
low, but greater than that of the general population because of the possibility of germline mosaicism.
Offspring of a proband. Each child of an individual with episodic ataxia type 1 has a 50% chance of inheriting the mutation.
Other family members. The risk to other family members depends on the status of the proband's parents. If a parent is
affected, his or her family members may be at risk.
Related Genetic Counseling Issues
Considerations in families with an apparent de novo mutation. When neither parent of a proband with an autosomal
dominant condition has the disease-causing mutation or clinical evidence of the disorder, it is likely that the proband has a de
novo mutation. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted
reproduction) or undisclosed adoption could also be explored.
Family planning
The optimal time for determination of genetic risk is before pregnancy. Similarly, decisions about testing to determine th
genetic status of at-risk asymptomatic family members are best made before pregnancy.
It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options)
to young adults who are affected or at risk of being affected.
DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that
testing methodology and our understanding of genes, mutations, and diseases will improve in the future, consideration should
be given to banking DNA of affected individuals. See  for a list of laboratories offering DNA banking.
Prenatal Testing
Prenatal diagnosis for pregnancies at increased risk is possible by analysis of DNA extracted from fetal cells obtained by
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amniocentesis usually performed at approximately 15 to 18 weeks’ gestation or chorionic villus sampling (CVS) at approximately
ten to 12 weeks’ gestation. The disease-causing allele of an affected family member must be identified in the family before
prenatal testing can be performed.
Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period o
by ultrasound measurements.
Preimplantation genetic diagnosis (PGD) may be available for families in which the disease-causing mutation has been
identified. For laboratories offering PGD, see .
Note: It is the policy of GeneReviews to include in GeneReviews™ chapters any clinical uses of testing available from
laboratories listed in the GeneTests™ Laboratory Directory; inclusion does not necessarily reflect the endorsement of such uses
by the author(s), editor(s), or reviewer(s).
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the
benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by
other organizations. For information on selection criteria, click here.
Ataxia UK
Lincoln House
1-3 Brixton Road
London SW9 6DE
United Kingdom
Phone: 0845 644 0606 (helpline); 020 7582 1444 (office); +44 (0) 20 7582 1444 (from abroad)
Email: helpline@ataxia.org.uk; office@ataxia.org.uk
www.ataxia.org.uk
euro-ATAXIA (European Federation of Hereditary Ataxias)
Ataxia UK
9 Winchester House
Kennington Park
London SW9 6EJ
United Kingdom
Phone: +44 (0) 207 582 1444
Email: marco.meinders@euro-ataxia.eu
www.euro-ataxia.eu
International Network of Ataxia Friends (INTERNAF)
Email: internaf-owner@yahoogroups.com
www.internaf.org
National Ataxia Foundation
2600 Fernbrook Lane
Suite 119
Minneapolis MN 55447
Phone: 763-553-0020
Email: naf@ataxia.org
www.ataxia.org
WE MOVE: Worldwide Education and Awareness for Movement Disorders
204 West 84th Street
New York NY 10024
Phone: 866-546-3136 (toll-free)
Fax: 212-875-8389
Email: wemove@wemove.org
www.wemove.org
Consortium for Clinical Investigation of Neurologic Channelopathies Contact Registry
Contact Registry
National Ataxia Registry
Department of Neurology, McKnight Brain Institute at University of Florida
100 South Newell Drive
L1-108
PO Box 100236
Gainesville FL 32610-0236
Phone: 352-273-9194
Fax: 352-392-8058
Email: nationalataxiaregistry@neurology.ufl.edu
www.nationalataxiaregistry.org
Molecular Genetics
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may
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contain more recent information. —ED.
Table A. Episodic Ataxia Type 1: Genes and Databases
Gene
Symbol
Chromosomal
Locus
Protein Name Locus Specific HGMD
KCNA1 12p13.32 Potassium voltage-gated channel subfamily A
member 1
KCNA1 homepage - Mendelian
genes
KCNA1
Data are compiled from the following standard references: gene symbol from HGNC; chromosomal locus, locus name, critical region, complementation
group from OMIM; protein name from UniProt. For a description of databases (Locus Specific, HGMD) to which links are provided, click here.
Table B. OMIM Entries for Episodic Ataxia Type 1 (View All in OMIM)
160120 EPISODIC ATAXIA, TYPE 1; EA1
176260 POTASSIUM CHANNEL, VOLTAGE-GATED, SHAKER-RELATED SUBFAMILY, MEMBER 1; KCNA1
Molecular Genetic Pathogenesis
Voltage-gated potassium channels (Kv) play key roles in neurotransmission and nerve cell physiology. Kv channels shorten the
duration of action potentials, modulate the release of neurotransmitters, and control the excitability, electrical properties, and
firing pattern of central and peripheral neurons [Hille 2001, Pessia 2004]. In particular, Kv1.1 channels (encoded by KCNA1)
regulate neuromuscular transmission, control the release of β-aminobutyric acid (GABA) from cerebellar basket cells onto
Purkinje cells [Herson et al 2003], and modulate synaptic transmission in hippocampus [Geiger & Jonas 2000].
Nomenclature of Kv channels is organized by subfamilies based on sequence relatedness by using the abbreviation Kvy.x
whereby the prefix specifies both the permeating ion (K ) and the voltage-dependence of the channel (v). According to this
standardized nomenclature Shaker-related channels have been classified in the subfamily Kv1.x and each member numbered
Kv1.1 through Kv1.9. The same criteria have been used to classify auxiliary subunits (Kvβ1.1 and Kvβ1.2) and channels related to
the subfamilies Shab (Kv2.1 and Kv2.2), Shaw (Kv3.1 to 3.4) and Shal (Kv4.1 to Kv4.3).
Functional homomeric Kv1.1 channels are tetrameric structures composed of four identical monomers. Each monomer is
encoded by KCNA1.
However, potassium channel diversity is greatly enhanced by the ability of different types of pore-forming subunits to
heteropolymerize and to form channels with properties different from the parental homomeric channels. Kv channels may
exhibit fast N-type inactivation that is caused by a “ball-and-chain” mechanism of pore occlusion. Fast inactivation may be
conferred to non-inactivating channels by auxiliary subunits such as Kvβ1.1 and Kvβ1.2. Four β subunits participate to the ion
channel complex and provide four inactivation particles. Notable examples:
Heteromeric channels composed of Kv1.1 and Kv1.2 that are expressed at cerebellar basket cell terminals and at the
juxtaparanodal region of motor axons
Channels composed of Kv1.1, Kv1.4, and, Kvβ1.1 subunits that are expressed in hippocampal mossy fiber boutons
Kv1.1 channels possess a slower process of inactivation, which has been named C-type or P-type depending on the structural
determinants of this process that have been located within the C-terminus and pore region.
D’Adamo et al first demonstrated that KCNA1 mutations associated with EA1 alter the expression and gating properties of
heteromeric channels composed of human Kv1.2 and Kv1.1 subunits [D’Adamo et al 1999, Rea et al 2002]. Successively, it has
been shown that KCNA1 mutations also impair the function of hetero-oligomeric complexes comprising Kv1.1, Kv1.4, and Kvβ1.x
subunits in distinct ways [Imbrici et al 2006, Imbrici et al 2011]. These studies raised the question as to whether other allelic
variations, whose gene products may or may not form hetero-oligomeric complexes with Kv1.1 subunits, may underlie a similar
channelopathy.
Normal allelic variants. KCNA1 has a transcript of 7983 nucleotides with a coding region of 1488. There are two exons, but
the coding region is located entirely within exon 2. In 5% of control chromosomes analyzed by Zuberi et al [1999] two silent
changes in the coding sequence were observed, c.684T>C and c.804G>C (see Table 3). The reference sequences in Table 3
include the correction of a sequence error published by Ramaswami et al [1990] and reported by Browne et al [1994] and Zuberi
et al [1999].
Pathologic allelic variants. To date, 23 KCNA1 mutations have been identified by sequence analysis (see Figure 1). Most are
missense mutations that are distributed throughout the gene; however, nonsense and small deletion mutations have also been
identified [Eunson et al 2000, Shook et al 2008].
Interestingly, four different mutations of the highly conserved threonine 226 residue, located within the second transmembrane
segment, have been identified [Rajakulendran et al 2007]. In particular, the p.Thr226Arg mutation is associated with epilepsy,
infantile contractures, postural abnormalities, and skeletal deformities. Although, the defects caused by the p.Thr226Ala,
p.Thr226Arg, and p.Thr226Met mutations on channel functions are virtually identical, they lead to diverse phenotypes.
Table 3. Selected KCNA1 Allelic Variants
+
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Class of Variant Allele
DNA Nucleotide Change
(Alias ) Protein Amino Acid Change Reference Sequences
Normal
c.684T>C
(C684T)
p.= 
NM_000217.2
NP_000208.2
c.804G>C
(C804G)
p.= 
Pathologic
c.676A>G p.Thr226Ala
c.677C>G p.Thr226Arg
c.677C>T p.Thr226Met
c.1222G>T p.Val408Leu
c.1241T>G p.Phe414Cys
c.1249C>T p.Arg417X
c.748_750delTTC p.Phe250del
See Quick Reference for an explanation of nomenclature. GeneReviews follows the standard naming conventions of the Human Genome Variation
Society (www.hgvs.org).
1. Variant designation that does not conform to current naming conventions
2. p.= designates that protein has not been analyzed, but no change is expected.
Normal gene product. KCNA1 encodes the voltage-gated K  channel Kv1.1. The predicted 496-amino acid Kv1.1 protein
contains six hydrophobic segments with the N- and C-termini residing inside the cell. The S4 segment of each Kv1.1 subunit
comprises the main voltage sensor that opens the channel by undergoing a conformational rearrangement upon membrane
depolarization. The S5-S6 loop (H5 region) contributes to the ion-conducting pore. The GYG residues, residing within this loop,
control the K  selectivity of the channel (see also Molecular Genetic Pathogenesis).
Abnormal gene product. The molecular mechanisms underlying episodic ataxia type 1 have been established by determining
the functional properties of wild-type and several mutant channels in Xenopus oocytes or mammalian cell lines [Adelman et al
1995, D’Adamo et al 1998, Zerr et al 1998, D’Adamo et al 1999, Zuberi et al 1999, Eunson et al 2000, Manganas et al 2001,
Imbrici et al 2003, Cusimano et al 2004, Imbrici et al 2006, Imbrici et al 2007, Imbrici et al 2008, Imbrici et al 2009, Imbrici et
al 2011]. Overall, these studies have shown that allelic variations underlying EA1 impair channel function and reduce the
outward K  flux through the channel, although with highly variable effects on aspects of channel expression and gating.
Regarding channel gating, KCNA1 mutations may alter the protein structure and affect the kinetics of opening and closing,
voltage dependence, and N- and C-type inactivation [D’Adamo et al 1998, D’Adamo et al 1999, Maylie et al 2002, Imbrici et al
2006, Imbrici et al 2009, Imbrici et al 2011].
Individuals with EA1 are heterozygous for a KCNA1 disease-causing mutation, possessing a normal and a mutated allele, which
may be equally expressed. Therefore, channels composed of wild-type and mutated subunits may be formed. Co-expression
systems, which mimic the heterozygous condition, have shown that some mutant subunits exert dominant negative effects on
wild-type subunits, resulting in less than half the normal current, whereas others have virtually no effect on surface expression.
It has been shown that KCNA1 allelic variations also alter the function of heteromeric channels containing different subunits,
demonstrating that mutations in a single gene disrupt the functions of other closely related proteins [D’Adamo et al 1999, Rea e
al 2002, Imbrici et al 2006]. Based on these findings, a model accounting for the cerebellar symptoms of EA1 was proposed by
D’Adamo and colleagues (see Figure 2).
A mouse model of EA1 has been generated by introducing a mutation analogous to the human p.Val408Ala mutation into the
murine ortholog, Kcna1. These animals showed impaired motor performance and altered cerebellar GABAergic transmission
from the basket cells to the Purkinje cells [Herson et al 2003]. Such Kv1.1 knock-in ataxic mice also exhibited spontaneous
myokymic activity exacerbated by fatigue, ischemia, and low temperature [Brunetti et al 2012]. Spontaneous myokymic
discharges were present despite motor nerve axotomy, suggesting that the motor nerve is an important generator of myokymic
activity. This study also showed that altered Ca  homeostasis in motor axons of mutant animals may contribute to spontaneou
myokymic activity [Brunetti et al 2012].
The causes that trigger the paroxysms of ataxia remain elusive, although a phenomenon akin to spreading acidification of the
cerebellar cortex has been suggested [Chen et al 2005b].
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Figures
Figure 1. Schematic drawing of the conventional membrane topology of a human Kv1.1 subunit. Four such subunits comprise a
functional homotetrameric channel. Different subunits belonging to the Kv1 subfamily may form heterotetrameric channels.
The positions of mutations identified to date in individuals with EA1 are indicated [D’Adamo et al 2012].
Modified from D’Adamo et al 2012. Reused by permission of Nova Science Publishers, Inc.
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Figure 2. Proposed effects of EA1-causing mutations on basket cell and Purkinje cell inhibitory outputs.
The diagram shows a basket cell which has synapses on the initial segment and soma of a number of Purkinje cells from the
cerebellar cortex of a normal individual (left) compared to an individual with EA1 (right). The reduced delayed rectifier function
of EA1 heteromeric channels comprising Kv1.1 and Kv1.2 subunits, which are expressed at the presynaptic level of basket cells,
may increase the membrane excitability, prolong their action potential duration, and enhance Ca  ion influx. Larger amounts o
γ-aminobutyric acid (GABA) may be released from basket cell terminals reducing the inhibitory outputs of the relevant Purkinje
cells. As a result, the output of the entire cerebellum to the rest of the brain may be markedly altered leading to the cerebellar
symptoms characteristic of EA1 syndrome (see D’Adamo et al 1999, Figure 7).
Reused by permission of FASEB Journal
Copyright © 1993-2013, University of Washington, Seattle. All rights reserved.
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